Clinical and laboratory data of the patients analyzed in this study
| . | N . |
|---|---|
| No. of patients | 284 |
| Age, y | |
| Range | 18-89 |
| Median | 60.5 |
| Sex | |
| Female | 163 |
| Male | 121 |
| FAB class | |
| AUL | 2 |
| Biphenotypic | 3 |
| ALL | 4 |
| AML M0 | 6 |
| AML M1 | 63 |
| AML M2 | 49 |
| AML M3 | 28 |
| AML M4 | 39 |
| AML M5 | 21 |
| AML M6 | 4 |
| MDS | 3 |
| AML with unknown FAB | 52 |
| Patients without clinical data | 10 |
| WBC count, 109/L | |
| Median | 50 |
| Range | 12-16 |
| Cytogenetic abnormality | |
| Favorable | 29 |
| Intermediate | 185 |
| Adverse | 11 |
| Unknown | 59 |
| . | N . |
|---|---|
| No. of patients | 284 |
| Age, y | |
| Range | 18-89 |
| Median | 60.5 |
| Sex | |
| Female | 163 |
| Male | 121 |
| FAB class | |
| AUL | 2 |
| Biphenotypic | 3 |
| ALL | 4 |
| AML M0 | 6 |
| AML M1 | 63 |
| AML M2 | 49 |
| AML M3 | 28 |
| AML M4 | 39 |
| AML M5 | 21 |
| AML M6 | 4 |
| MDS | 3 |
| AML with unknown FAB | 52 |
| Patients without clinical data | 10 |
| WBC count, 109/L | |
| Median | 50 |
| Range | 12-16 |
| Cytogenetic abnormality | |
| Favorable | 29 |
| Intermediate | 185 |
| Adverse | 11 |
| Unknown | 59 |
Favorable, intermediate, and unfavorable cytogenetic abnormality has been defined according to published data.64
AUL indicates acute undifferentiated leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; and WBC, white blood cell.